The company will take on Novo Nordisk in reviving the CB1 inhibitor mechanism to develop a more tolerable long-term weight loss drug, after exiting ophthalmology.
Skye Bioscience has abandoned its plans in ophthalmology after a Phase II failure and will now focus exclusively on its obesity candidate, the cannabinoid 1 receptor (CB1) inhibitor nimacimab.
The withdrawal of Sanofi’s CB1 inhibitor Acomplia set back obesity drugs for a decade.
The immediate market response to the news on 10 June was not positive, with Skye’s share price falling by nearly...
Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.
Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.
The company said it will no longer use ALLO-647 after a patient developed a fatal adenovirus infection, and it will pursue further development of its Dagger technology to minimize or eliminate the need for lymphodepletion.
